```
=> b reg
FILE 'REGISTRY' ENTERED AT 13:03:49 ON 08 JAN 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    6 JAN 2010  HIGHEST RN 1201136-14-2
DICTIONARY FILE UPDATES:   6 JAN 2010  HIGHEST RN 1201136-14-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d que sta l9
L7              STR
```




```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  17

STEREO ATTRIBUTES: NONE
L9          665 SEA FILE=REGISTRY SSS FUL L7

100.0% PROCESSED    2627 ITERATIONS                          665 ANSWERS
SEARCH TIME: 00.00.01



=> b zcap
FILE 'ZCAPLUS' ENTERED AT 13:04:04 ON 08 JAN 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS is
strictly prohibited.

FILE COVERS 1907 - 8 Jan 2010  VOL 152 ISS 3
```

FILE LAST UPDATED: 7 Jan 2010 (20100107/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2009

ZCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs hitrn fhitstr l12 tot

L12 ANSWER 1 OF 1 ZCAPLUS COPYRIGHT 2010 ACS on STN
AN 2005:638879 ZCAPLUS
DN 143:153410
TI Preparation of piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds as inducers of cytokine biosynthesis for treatment of viral and neoplastic diseases
IN Kshirsagar, Tushar A.; Griesgraber, George W.; Celebi, Abdulaziz A.; Heppner, Philip D.
PA 3M Innovative Properties Company, USA
SO PCT Int. Appl., 218 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2005066172	A1	20050721	2004WO-US0043474	20041222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU--2004312510	A1	20050721	2004AU-000312510	20041222
CA-----2552101	A1	20050721	2004CA-002552101	20041222
EP-----1699792	A1	20060913	2004EP-000815538	20041222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN-----1922178	A	20070228	2004CN-080042200	20041222
JP---2007530450	T	20071101	2006JP-000547424	20041222
IN---200602371	A	20070706	2006IN-000002371	20060628
US-20070167476	A1	20070719	2007US-000596895	20070116
PRAI 2003US-0533204P	P	20031229		
2004WO-US0043474	W	20041222		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS CASREACT 143:153410; MARPAT 143:153410
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [RA, RB = independently H, halo, alk(en)yl, alkoxy, alkylthio, NH2 and derivs.; or RACCRB = (un)substituted fused hetero/aryl, fused 5- to 7-membered saturated ring; X = a bond, alkylene; Z = (un)substituted alkylene; with the proviso that the total number of C atoms contributed by X and Z = 1-3; Y = a bond, SO2, SO2-NH and derivs., CO, etc.; R = halo, OH, alk(en)yl, haloalkyl, alkoxy, alkylthio, NH2 and derivs.; R1 = H, (un)substituted alk(en/yn)yl, hetero/aryl, etc. with proviso; and their pharmaceutically acceptable salts], were prepared as immunomodulators for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases. For example, II was prepared via cyclocondensation of 1,2-diamine derivative III with chloroacetyl chloride, cyclization of imidazoquinoline, BOC-deprotection, chlorosulfonation of amine (not isolated) with MeSO2Cl, oxidation/amination with NH4OH, and TBDMS-deprotection. Certain I modulated cytokine biosynthesis by inhibiting production of interferon α and/or tumor necrosis factor TNF-α when tested in an in vitro blood cell system.

IT **1044675-88-8** **1044675-97-9** **1044676-02-9**
RL: PRPH (Prophetic)
(Preparation of piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds as inducers of cytokine biosynthesis for treatment of viral and neoplastic diseases)

L12 ANSWER 1 OF 1 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)
860164-31-4P **860164-33-6P** **860164-35-8P**
860164-37-0P **860164-39-2P** **860164-41-6P**
860164-43-8P **860164-45-0P** **860164-47-2P**
860164-49-4P **860164-51-8P** **860164-53-0P**
860164-55-2P **860164-57-4P** **860164-59-6P**
860164-61-0P **860164-63-2P** **860164-65-4P**
860164-67-6P **860164-69-8P** **860164-71-2P**
860164-73-4P **860164-75-6P** **860164-77-8P**
860164-79-0P **860164-81-4P** **860164-83-6P**
860164-85-8P **860164-87-0P** **860164-89-2P**
860164-91-6P **860164-93-8P** **860164-95-0P**
860164-97-2P **860164-99-4P** **860165-01-1P**
860165-03-3P **860165-05-5P** **860165-07-7P**
860165-09-9P **860165-11-3P** **860165-13-5P**
860165-15-7P **860165-16-8P** **860165-18-0P**
860165-20-4P **860165-22-6P** **860165-24-8P**
860165-26-0P **860165-28-2P** **860165-30-6P**
860165-32-8P **860165-34-0P** **860165-36-2P**
860165-38-4P **860165-40-8P** **860165-42-0P**
860165-44-2P **860165-46-4P** **860165-48-6P**
860165-50-0P **860165-52-2P** **860165-54-4P**
860165-56-6P **860165-58-8P** **860165-60-2P**
860165-62-4P **860165-64-6P** **860165-66-8P**
860165-68-0P **860165-70-4P** **860165-72-6P**
860165-74-8P **860165-76-0P** **860165-78-2P**
860165-80-6P **860165-82-8P** **860165-84-0P**
860165-86-2P **860165-88-4P** **860165-90-8P**
860165-92-0P **860165-94-2P** **860165-96-4P**
860165-98-6P **860166-00-2P** **860166-02-8P**
860166-04-7P **860166-06-9P** **860166-08-1P**
860166-10-5P **860166-12-7P** **860166-14-9P**
860166-16-1P **860166-18-3P** **860166-20-7P**
860166-22-9P **860166-24-1P** **860166-26-3P**
860166-28-5P **860166-30-9P** **860166-32-1P**
860166-34-3P **860166-36-5P** **860166-38-7P**
860166-40-1P **860166-42-3P** **860166-44-5P**
860166-46-7P **860166-48-9P** **860166-50-3P**
860166-52-5P **860166-54-7P** **860166-56-9P**
860166-58-1P **860166-60-5P** **860166-62-7P**
860166-64-9P **860166-66-1P** **860166-68-3P**
860166-70-7P **860166-72-9P** **860166-74-1P**
860166-76-3P **860166-78-5P** **860166-80-9P**
860166-82-1P **860166-84-3P** **860166-86-5P**
860166-88-7P **860166-90-1P** **860166-92-3P**
860166-94-5P **860166-96-7P** **860166-98-9P**
860167-00-6P **860167-02-8P** **860167-04-0P**
860167-06-2P **860167-08-4P** **860167-10-8P**
860167-12-0P **860167-14-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of fused imidazo ring compds. as inducers of cytokine biosynthesis for treatment of viral and neoplastic disease)

IT **860167-16-4P** **860167-18-6P** **860167-20-0P**
860167-22-2P **860167-24-4P** **860167-26-6P**
860167-28-8P **860167-30-2P** **860167-32-4P**
860167-34-6P **860167-36-8P** **860167-38-0P**
860167-40-4P **860167-42-6P** **860167-44-8P**
860167-46-0P **860167-48-2P** **860167-49-3P**,
9-(Methylsulfonyl)-2,3,4,8,9,10,11,12-octahydro-1H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-6-amine
860167-52-8P, 9-(Methylsulfonyl)-3-(pyridin-3-yl)-9,10,11,12-tetrahydro-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-6-amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of fused imidazo ring compds. as inducers of cytokine biosynthesis for treatment of viral and neoplastic disease)

IT **860170-00-9P**, 6-Amino-9-(methylsulfonyl)-9,10,11,12-tetrahydro-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-3-ol
860173-13-3P, 9,10,11,12-Tetrahydro-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-6-amine hydrochloride
860173-16-6P, tert-Butyl 6-amino-11-[(tert-butyldimethylsilyl)oxy]-11,12-dihydro-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinoline-9(10H)-

L12 ANSWER 1 OF 1 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)
IT **860160-34-5P**, 11-[(tert-Butyldimethylsilyl)oxy]-9-(methylsulfonyl)-9,10,11,12-tetrahydro-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-6-amine
860160-40-3P **860160-41-4P**,
9-(Methylsulfonyl)-9,10,11,12-tetrahydro-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-6-amine
860167-51-7P, 3-Bromo-9-(methylsulfonyl)-9,10,11,12-tetrahydro-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-6-amine
860167-54-0P **860167-56-2P** **860167-58-4P**
860167-60-8P **860167-62-0P** **860167-64-2P**
860167-66-4P **860167-68-6P** **860167-70-0P**
860167-72-2P **860167-74-4P** **860167-76-6P**
860167-78-8P **860167-80-2P** **860167-82-4P**
860167-84-6P **860167-86-8P** **860168-85-0P**
860168-87-2P **860168-89-4P** **860168-91-8P**
860168-93-0P **860168-95-2P** **860168-97-4P**
860168-99-6P **860169-01-3P** **860169-03-5P**
860169-05-7P **860169-07-9P** **860169-09-1P**
860169-11-5P **860169-13-7P** **860169-15-9P**
860169-17-1P **860169-19-3P** **860169-21-7P**
860169-23-9P **860169-25-1P** **860169-27-3P**
860169-29-5P **860169-31-9P** **860169-32-0P**
860169-34-2P **860169-36-4P** **860169-38-6P**
860169-40-0P **860169-42-2P** **860169-44-4P**
860169-46-6P **860169-48-8P** **860169-50-2P**
860169-52-4P **860169-54-6P** **860169-56-8P**
860169-59-1P **860169-61-5P** **860169-64-8P**
860169-67-1P **860169-69-3P** **860169-71-7P**
860169-73-9P **860169-76-2P** **860169-79-5P**
860169-82-0P **860169-85-3P** **860169-87-5P**
860169-90-0P **860169-93-3P** **860169-96-6P**
860169-98-8P **860170-01-0P** **860170-04-3P**
860170-07-6P **860170-10-1P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of fused imidazo ring compds. as inducers of cytokine biosynthesis for treatment of viral and neoplastic disease)

IT **860160-35-6P**, 6-Amino-9-(methylsulfonyl)-9,10,11,12-tetrahydro-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-1-ol
860160-42-5P **860162-53-4P** **860162-55-6P**
860162-57-8P **860162-59-0P** **860162-61-4P**
860162-63-6P **860162-65-8P** **860162-67-0P**
860162-69-2P **860162-71-6P** **860162-73-8P**
860162-75-0P **860162-77-2P** **860162-79-4P**
860162-81-8P **860162-83-0P** **860162-85-2P**
860162-87-4P **860162-89-6P** **860162-91-0P**
860162-93-2P **860162-95-4P** **860162-97-6P**
860162-99-8P **860163-01-5P** **860163-03-7P**
860163-05-9P **860163-07-1P** **860163-09-3P**
860163-11-7P **860163-13-9P** **860163-15-1P**
860163-17-3P **860163-19-5P** **860163-21-9P**
860163-23-1P **860163-25-3P** **860163-27-5P**
860163-29-7P **860163-31-1P** **860163-33-3P**
860163-35-5P **860163-37-7P** **860163-39-9P**
860163-41-3P **860163-43-5P** **860163-45-7P**
860163-47-9P **860163-49-1P** **860163-51-5P**
860163-53-7P **860163-55-9P** **860163-57-1P**
860163-59-3P **860163-61-7P** **860163-63-9P**
860163-65-1P **860163-67-3P** **860163-69-5P**
860163-71-9P **860163-73-1P** **860163-75-3P**
860163-77-5P **860163-79-7P** **860163-81-1P**
860163-83-3P **860163-85-5P** **860163-87-7P**
860163-89-9P **860163-91-3P** **860163-93-5P**
860163-95-7P **860163-97-9P** **860163-99-1P**
860164-01-8P **860164-03-0P** **860164-05-2P**
860164-07-4P **860164-09-6P** **860164-11-0P**
860164-13-2P **860164-15-4P** **860164-17-6P**
860164-19-8P **860164-21-2P** **860164-23-4P**
860164-25-6P **860164-27-8P** **860164-29-0P**

L12 ANSWER 1 OF 1 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)
carboxylate **860173-17-7P**,
11-[(tert-Butyldimethylsilyl)oxy]-9,10,11,12-tetrahydro-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-6-amine hydrochloride
860173-23-5P, 3-Bromo-9,10,11,12-tetrahydro-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-6-amine
860173-35-9P, tert-Butyl 6-amino-3-benzyloxy-11,12-dihydro-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinoline-9(10H)-carboxylate
860173-36-0P, 3-Benzyloxy-9,10,11,12-tetrahydro-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-6-amine dihydrochloride
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of fused imidazo ring compds. as inducers of cytokine biosynthesis for treatment of viral and neoplastic disease)

IT **1043593-39-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of fused imidazo ring compds. as inducers of cytokine biosynthesis for treatment of viral and neoplastic disease)

IT **1044675-88-8**
RL: PRPH (Prophetic)
(Preparation of piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds as inducers of cytokine biosynthesis for treatment of viral and neoplastic diseases)

RN 1044675-88-8 ZCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib abs hitrn fhitstr l13 tot

L13 ANSWER 1 OF 1 ZCAPLUS COPYRIGHT 2010 ACS on STN
AN 2006:677628 ZCAPLUS
DN 145:145757
TI Preparation of chiral fused [1,2]imidazo[4,5-c] ring compounds as inducers of cytokine biosynthesis for treatment of viral and neoplastic diseases
IN Griesgraber, George W.; Kshirsagar, Tushar A.; Celebi, Abdulaziz A.; Johannessen, Sarah C.; Danielson, Michael E.; Rice, Michael J.; Wurst, Joshua R.
PA 3M Innovative Properties Company, USA
SO PCT Int. Appl., 257 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2006074003	A2	20060713	2005WO-US047258	20051229
WO--2006074003	A3	20071122		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU--2005322898	A1	20060713	2005AU-000322898	20051229
CA-----2592904	A1	20060713	2005CA-002592904	20051229
EP-----1831226	A2	20070912	2005EP-000855766	20051229
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP--2008526754	T	20080724	2007JP-000549590	20051229
US-20080269192	A1	20081030	2007US-000813039	20070628
PRAI 2004US-00640614P	P	20041230		
2005US-00697257P	P	20050707		
2005WO-US047258	W	20051229		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS CASREACT 145:145757; MARPAT 145:145757
GI



I



II



III

AB Title compds. I [X = a bond, straight or branched alkylene, optionally having a substituent at a C other than the C adjacent to a heteroatom; X' = straight or branched alkylene, optionally having a substituent at a C other than the C adjacent to a heteroatom; provided that the sum of the

L13 ANSWER 1 OF 1 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)
ring C atoms contributed by X and X' = 1-3; Z = O, NH and derivs., N-SO2-NH- and derivs., etc.; X1 = a bond, alk(en/yn)ylene; R1 = (un)substituted alk(en/yn)yl, hetero/aryl, etc.; RA, RB = independently H, halo, alk(en)yl, alkoxy, etc.; or when taken together RA and RB form a (un)substituted fused hetero/aryl ring, or a (un)substituted fused 5 to 7 membered satd. ring; and their pharmaceutically acceptable salts], were prepd. as immunomodulators for inducing cytokine biosynthesis in animals (no data) and in the treatment of diseases including viral and neoplastic diseases (no data). For example, II was prepd. via cyclocondensation of diamine III (prepn. given) with Et 2-chloroethanimidoate•HCl, followed by TBDMS-deprotection in the presence of tetrabutylammonium fluoride/cyclization in THF, oxidn., and amination with NH4OH. Certain I modulated cytokine biosynthesis by inhibiting prodn. of interferon α and/or tumor necrosis factor TNF-α when tested in an in vitro blood cell system (no data).
IT **898818-25-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of chiral fused [1,2]imidazo[4,5-c] ring compds. as inducers of cytokine biosynthesis for treatment of viral and neoplastic diseases)
IT **898818-25-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of chiral fused [1,2]imidazo[4,5-c] ring compds. as inducers of cytokine biosynthesis for treatment of viral and neoplastic diseases)
RN 898818-25-2 ZCAPLUS
CN Formic acid, compd. with 9,10,11,12-tetrahydro-12-methyl-9-(methylsulfonyl)-8H-[1,4]diazepino[1',2':1,2]imidazo[4,5-c]quinolin-6-amine (1:?) (CA INDEX NAME)

CM 1

CRN 898818-24-1
CMF C16 H19 N5 O2 S



CM 2

CRN 64-18-6
CMF C H2 O2

```
=> d his

     (FILE 'HOME' ENTERED AT 12:53:49 ON 08 JAN 2010)

     FILE 'ZCAPLUS' ENTERED AT 12:54:31 ON 08 JAN 2010
L1            1 US20070167476/PN

     FILE 'REGISTRY' ENTERED AT 12:54:56 ON 08 JAN 2010

     FILE 'ZCAPLUS' ENTERED AT 12:54:56 ON 08 JAN 2010
L2               TRA L1 1- RN :     1057 TERMS

     FILE 'REGISTRY' ENTERED AT 12:55:16 ON 08 JAN 2010
L3          1057 SEA L2
L4           529 L3 AND NRRS>=4
L5               STR
L6            37 L5
L7               STR L5
L8            36 L7
L9           665 L7 FULL
                 SAV TEM J895C2A/A L9
L10          342 L9 AND L3
L11          323 L9 NOT L10

     FILE 'ZCAPLUS' ENTERED AT 13:01:51 ON 08 JAN 2010
L12             1 L10
L13             1 L11

=>
```